Interventional cardiology

Hypertension: there’s more work to be done beyond triple therapy

Spironolactone appears to be the front-runner for preferred fourth-line pharmacotherapy in patients with resistant hypertension. According to a review of the evidence, the mineralocorticoid receptor agonist is probably the best add-on therapy in patients with high blood pressure despite maximal doses of guideline-recommended triple therapy. Co-author Professor Markus Schlaich, head of the Dobney Hypertension Centre ...

Already a member?

Login to keep reading.

© 2021 the limbic